Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18 FEF 5 and positron emission tomography

Donald T.T. Yapp, Janet Woo, Aileen Kartono, Jonathan Sy, Thomas Oliver, Kirsten A. Skov, Cameron J. Koch*, Hans Adomat†, Wieslawa H. Dragowska, Ladan Fadzli†, Thomas Ruth‡, Michael J. Adam‡, David Green‡ and Martin Gleave† The Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, BC, Canada, *The Department of Radiation Oncology, University of Pennsylvania, Philadelphia PA, USA, †The Prostate Centre at Vancouver General Hospital, and ‡Tri-University Meson Facility (TRIUMF), Vancouver, BC, Canada

[1]  V. Gebski,et al.  The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  B J Krause,et al.  PET and PET/CT studies of tumor tissue oxygenation. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[3]  D. Fraker,et al.  EF5 binding and clinical outcome in human soft tissue sarcomas. , 2006, International journal of radiation oncology, biology, physics.

[4]  R. Bristow,et al.  Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  K. Haustermans,et al.  Hypoxia in head and neck cancer: How much, how important? , 2005, Head & neck.

[6]  P. Kozlowski,et al.  Serial tumour blood‐flow measurements in androgen‐dependent and ‐independent Shionogi tumour models , 2005, BJU international.

[7]  S. Siegel,et al.  Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  J. McNab,et al.  Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[9]  K. Gelmon,et al.  HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. , 2004, Molecular cancer research : MCR.

[10]  M. Gleave,et al.  Hypoxia in the Androgen-Dependent Shionogi Model for Prostate Cancer at Three Stages1 , 2004, Radiation research.

[11]  C. Aquino-Parsons,et al.  Measurement of tumor hypoxia using single-cell methods. , 2004, Seminars in radiation oncology.

[12]  M. Gleave,et al.  Effect of time of castration and tumour volume on time to androgen‐independent recurrence in Shionogi tumours , 2004, BJU international.

[13]  J. Vishwanatha,et al.  Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model , 2003, BMC urology.

[14]  J. Karp,et al.  Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Alexandra L Hanlon,et al.  Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. , 2002, Urology.

[16]  T. J. Robnett,et al.  Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[17]  A. Hanlon,et al.  Hypoxia in Human Prostate Carcinoma: An Eppendorf Po2 Study , 2001, American journal of clinical oncology.

[18]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[19]  J. D. Chapman,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.

[20]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[21]  M. Gleave,et al.  Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. , 1999, Cancer research.

[22]  A. Pollack,et al.  Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. , 1999, International journal of radiation oncology, biology, physics.

[23]  B. Chauvet,et al.  [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[24]  A. Zietman,et al.  Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. , 1997, International journal of radiation oncology, biology, physics.

[25]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[26]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[27]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[28]  P. Olive,et al.  Heterogeneity in human tumour hypoxic fraction using the comet assay. , 1996, The British journal of cancer. Supplement.

[29]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[30]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.

[31]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[32]  N. Bruchovsky,et al.  Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. , 1988, Cancer research.

[33]  N. Bruchovsky,et al.  Classification of dependent and autonomous variants of shionogi mammary carcinoma based on heterogenous patterns of androgen binding , 1978, Cell.

[34]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[35]  Y. Fujibayashi,et al.  Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  A. Zietman,et al.  The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. , 1997, The cancer journal from Scientific American.

[37]  A. Giaccia,et al.  Tumour hypoxia: the picture has changed in the 1990s. , 1994, International journal of radiation biology.